CANARX Executives Charged Over Illegal Prescription Drug Importation Scheme
Federal authorities arrest CANARX treasurer for smuggling drugs into the United States.
1Federal Charges Against Executives
U.S. authorities have arrested John Thomas Howard, treasurer of the Canadian company CANARX, on charges of smuggling and conspiracy. His brother, Bob Howard, who serves as the company president, is also wanted in the federal investigation. The charges stem from an alleged long-running scheme to illegally import prescription drugs into the United States.
2Scope of the Investigation
The criminal complaint filed in court covers activities spanning from February 22, 2017, through April 15, 2026. Special agent Dustin Dobbs of the FDA's Office of Criminal Investigations led the probe. While the affidavit confirms probable cause for illegal importation, it does not specify the exact medications involved in the alleged smuggling operation.
3Alternative Funding Program Model
CANARX operates as an alternative funding program, or AFP, which provides high-cost specialty drugs to U.S. employers at lower prices. These companies often source medications from countries like Canada, the United Kingdom, Australia, and New Zealand. Employers sometimes mandate staff participation in these programs to manage rising healthcare costs for their employees.
4FDA Regulatory Stance
The FDA maintains that importing prescription drugs as substitutes for FDA-approved medications is illegal and poses significant safety risks. In 2019, the agency issued a warning letter to CANARX regarding unapproved drug distribution. By 2023, the FDA had seized shipments from the company, citing concerns that the medications were potentially misbranded or counterfeit.
5Company Defense Strategy
General counsel Joseph Morris stated that the Howard brothers deny all allegations and intend to defend themselves vigorously in court. Previously, the company argued that it sourced medicines from highly regulated countries and operated legally. They maintain that their model provides a necessary service for patients struggling with high domestic drug costs.
6Gilead Sciences Civil Lawsuit
Beyond the federal criminal charges, CANARX faces a pending civil lawsuit from Gilead Sciences. The pharmaceutical company accuses CANARX of illegally importing Biktarvy, a medication used to treat HIV. Gilead stated they are taking legal action to protect the integrity of the U.S. medicine supply chain and ensure patient safety standards are met.
7Legal Gray Areas
The core conflict involves the legality of importing prescription drugs for personal use. While the FDA allows limited personal importation when drugs are unavailable domestically, officials argue this does not apply to the systemic substitution of FDA-approved products. AFPs have built their business models on this specific interpretation of federal import regulations.
8Broader Industry Implications
This case highlights the growing tension between cost-saving healthcare initiatives and federal drug safety oversight. As drug prices remain high, the prevalence of AFPs has increased, drawing more scrutiny from regulators. The outcome of this criminal case could set a significant legal precedent for how third-party international drug providers operate within America.